The interim results on the first 415 patients randomized in the phase 3 ALPINE study showed a significantly better response for zanubrutinib compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic leukemia, said Peter Hillmen, PhD, MB ChB, professor at the University of Leeds.
The interim results on the first 415 patients randomized in the phase 3 ALPINE study showed a significantly better response for zanubrutinib compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic leukemia, said Peter Hillmen, PhD, MB ChB, professor at the University of Leeds and honorary consultant hematologist at Leeds Teaching Hospitals NHS Trust.
What do the interim results of the phase 3 ALPINE study of zanubritinib vs ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic leukemia show so far?
The ALPINE study compared zanubrutinib with ibrutinib, which are second-generation Bruton tyrosine kinase (BTK) inhibitors. The study is a large trial with 652 patients, but the interim results being presented at the European Hematology Association meeting are of the first 415 patients who were randomized.
The primary end point was overall response rate, which allowed for the trial to be reported earlier, and the follow-up is relatively short. The overall response was significantly better for zanubrutinib compared with ibrutinib at the 12-month time point, Hillmen explained. The outcome of the progression-free survival was also in favor of zanubrutinib, he added.
“As yet, not a significant difference in overall survival, although there is a trend to watch that space,” Hillmen said. “Also there’s a reduction, a significant reduction, in atrial fibrillation from 10% to 2.5% for zanu[brutinib].”
The study will be followed longer, the numbers will change, and there will be new adverse effects.
“There’s been a difference in hypertension, which is interesting, but that might be to do with the short follow-up,” Hillmen said. “So, I think we need further follow-up for the ALPINE study.”
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More